Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 6/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 6/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 6/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8906323 | 0.81 | AKT2 (0.44) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL932299 | 0.79 | ADORA2A (0.35) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL8823867 | 0.79 | ADORA2A (0.35) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL42335 | 0.79 | ADORA2A (0.61) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL7168415 | 0.79 | ADORA2A (0.35) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9010833 | 0.79 | ADORA2A (0.35) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5667619 | 0.79 | ADORA2A (0.43) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL11918991 | 0.79 | NUDT1 (0.36) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL16513158 | 0.79 | ADORA2A (0.35) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL94915 | 0.79 | ADORA2A (0.35) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108904505-B | Application of 6, 8-dihydroxypurine compound in preparation of anti-hepatitis B virus drugs | 中山大学 | 2020-05-22 | — | — | CN | claimed |
| EP-1670809-B1 | SYNTHESIS AND MANUFACTURE OF PENTOSTATIN AND ITS PRECURSORS, ANALOGS AND DERIVATIVES | MAYNE PHARMA PLC (GB) | 2016-01-13 | — | — | EP | claimed |
| JP-4830128-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| EP-1670809-A2 | SYNTHESIS AND MANUFACTURE OF PENTOSTATIN AND ITS PRECURSORS, ANALOGS AND DERIVATIVES | SuperGen, Inc. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050267056-A1 | Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives | MAYNE PHARMA (USA) INC. | 2005-12-01 | — | — | US | claimed |
| WO-2005027838-A2 | SYNTHESIS AND MANUFACTURE OF PENTOSTATIN AND ITS PRECURSORS, ANALOGS AND DERIVATIVES | SUPERGEN, INC. (US) | 2005-03-31 | — | — | WO | claimed |
| US-4533637-A | REPLACING SERUM WITH CYCLODEXTRINS | AJINOMOTO CO., INC. (JP) | 1985-08-06 | — | — | US | claimed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| US-20240105340-A1 | SURVIVAL PREDICTION USING METABOLOMIC PROFILES | BioAge Labs, Inc. | 2024-03-28 | — | — | US | disclosed |
| CN-117229980-B | Weissella sinica fermented feed and application and deodorization effect thereof | 北京市农林科学院 | 2024-01-30 | — | — | CN | disclosed |
| US-11881311-B1 | Survival prediction using metabolomic profiles | BioAge Labs, Inc. (US) | 2024-01-23 | — | — | US | disclosed |
| CN-117229980-A | Weissella sinica fermented feed and application and deodorization effect thereof | 北京市农林科学院 | 2023-12-15 | — | — | CN | disclosed |
| CN-108904505-B | Application of 6, 8-dihydroxypurine compound in preparation of anti-hepatitis B virus drugs | 中山大学 | 2020-05-22 | — | — | CN | disclosed |
| EP-1921143-A2 | Mutants of desoxycytidine kinase having extended enzymatic activity | INSTITUT PASTEUR (FR) | 2008-05-14 | — | — | EP | disclosed |
| EP-1383890-B1 | MUTANTS OF DESOXYCYTIDINE KINASE HAVING EXTENDED ENZYMATIC ACTIVITY | PASTEUR INSTITUT (FR) | 2008-05-14 | — | — | EP | disclosed |
| EP-1670809-A2 | SYNTHESIS AND MANUFACTURE OF PENTOSTATIN AND ITS PRECURSORS, ANALOGS AND DERIVATIVES | SuperGen, Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050267056-A1 | Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives | MAYNE PHARMA (USA) INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005027838-A2 | SYNTHESIS AND MANUFACTURE OF PENTOSTATIN AND ITS PRECURSORS, ANALOGS AND DERIVATIVES | SUPERGEN, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1383890-A2 | MUTANTS OF DESOXYCYTIDINE KINASE HAVING EXTENDED ENZYMATIC ACTIVITY | INSTITUT PASTEUR (FR) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002083892-A2 | MUTANTS OF DESOXYCYTIDINE KINASE HAVING EXTENDED ENZYMATIC ACTIVITY | INSTITUT PASTEUR (FR) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267056-A1 | Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives | UMPS, THPO, DHPS | ADORA2A 29/4885ADORA1 143/4885PI4KA 4395/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | ADORA2A 593/4885ADORA1 935/4885PI4KA 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.